Welcome to our dedicated page for Curative Biotechnology news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on Curative Biotechnology stock.
Curative Biotechnology, Inc. develops biomedical therapies with a current focus on degenerative eye diseases. Company news centers on its metformin-based topical ophthalmic formulation, a program supported by a worldwide exclusive license from the National Eye Institute at the NIH and a Cooperative Research and Development Agreement with the NEI. Updates also cover research agreements, clinical-supply manufacturing for sterile ophthalmic drops, and translational work spanning age-related macular degeneration and veterinary retinal degeneration models.
Recurring corporate developments include capital-structure actions such as the completed reverse stock split, strategic and financial advisory engagements, board and clinical-development governance updates, and material agreements tied to the company’s ophthalmology platform.
Summary not available.
Summary not available.
Curative Biotechnology Inc. (CUBT) announced on January 5, 2023, the successful completion of its IND enabling Tolerance and Toxicology Study of Metformin HCL Solution for eye drop use in rabbits. This milestone allows the company to prepare its IND application for a clinical trial targeting Intermediate Dry Age-Related Macular Degeneration (AMD) and Geographic Atrophy (GA). The studies address unmet medical needs, as no FDA-approved treatments currently exist for these conditions. The first human study will be conducted under a CRADA with the National Eye Institute.
Curative Biotechnology Inc. (CUBT) announced plans for an underwritten public offering of its common stock, following a 1-for-400 reverse stock split. The offering may include a 45-day option for the underwriter to purchase an additional 15% of shares. Proceeds will be allocated for working capital and corporate purposes. The offering is subject to market conditions and is expected to close by September 30, 2022, with trading on the NYSE American set to begin on October 3, 2022. Aegis Capital Corp. is the sole book-running manager for this offering.
Curative Biotechnology Inc. (OTC: CUBT) has appointed Lawrence S. Zaslow as an independent director, enhancing its Board of Directors. Zaslow, a co-founder of BioTheryX, Inc., brings extensive experience in strategic planning, capital raising, and corporate development. His leadership contributed to BioTheryX's $100 million financing round. Curative Biotech focuses on novel treatments for rare diseases, with ongoing programs in infectious disease, neuro oncology, and degenerative eye disease, including its pipeline candidates IMT504, CURB906, and a reformulated Metformin for Age-Related Macular Degeneration.
Curative Biotechnology Inc. (CUBT) announced the appointment of Cary Sucoff as an independent director on May 12, 2022. Sucoff brings over 35 years of experience in legal and securities sectors, having participated in financing for more than 100 public and private companies. His expertise encompasses legal compliance, corporate strategy, and capital markets. Sucoff is also involved with several healthcare and biotech firms, enhancing Curative Biotech's financial governance and oversight capabilities.
Curative Biotechnology Inc. (CUBT) has appointed Cary Sucoff as an independent director, enhancing its financial expertise amidst its focus on rare disease treatments. With over 35 years in legal and securities sectors, Sucoff brings extensive experience from his involvement in financing numerous public and private companies. He currently advises several healthcare firms and has held leadership roles in multiple committees across various boards. CUBT continues to develop innovative therapies, including treatments for infectious diseases and degenerative eye diseases.
Curative Biotechnology, Inc. (CUBT) announced a collaboration with the National Eye Institute (NEI) under a Cooperative Research and Development Agreement (CRADA) to advance its metformin formulation for treating Age-Related Macular Degeneration (AMD). The company is conducting a Good Laboratory Practice (GLP) toxicology study to evaluate the formulation's tolerability, pharmacokinetics, and ocular tissue distribution, crucial for an FDA Investigational New Drug (IND) filing. This study involves comprehensive ocular assessments by certified specialists.
Curative Biotechnology (OTC: CUBT) announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) on March 21, 2022. This collaboration aims to evaluate Curative's proprietary ocular metformin formulation for treating Age-Related Macular Degeneration (AMD), a leading cause of vision loss. The CRADA will last three years, with research under the supervision of Dr. Emily Chew from NEI, potentially addressing unmet medical needs in AMD therapy.
Curative Biotechnology (CUBT) announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) to study its ocular metformin formulation for treating Age-Related Macular Degeneration (AMD). The agreement, effective for three years, aims to address the unmet therapeutic needs for AMD, a leading cause of vision loss. Under the leadership of Dr. Emily Chew, the collaboration will explore clinical evaluations of this novel therapy.